Literature DB >> 1885426

Episodic acyclovir therapy to abort recurrent attacks of genital herpes simplex infection.

J D Whatley1, R N Thin.   

Abstract

Frequent recurrence of genital herpes simplex infection can be a distressing condition. Continuous suppressive oral acyclovir is effective but expensive. Hitherto episodic therapy has given disappointing results. An open comparative study of patient initiated therapy is reported here. Acyclovir 200 mg five times daily for five days aborted 44% of recurrences and shortened 38% by greater than or equal to 50%, giving useful response in 82% of 34 recurrences. Acyclovir 400 mg twice daily for five days aborted 60% and shortened 17% giving useful benefit in 77% of 20 recurrences. Acyclovir 200 mg twice a day for five days gave unsatisfactory results. Patients were selected for frequent recurrences and a recognized prodrome, and care was taken to help to identify early prodromal symptoms. In these patients acyclovir in dosages of 200 mg five times daily for five days and 400 mg bd for five days proved convenient and cost effective.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1885426     DOI: 10.1093/jac/27.5.677

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir.

Authors:  A Strand; R Patel; H C Wulf; K M Coates
Journal:  Sex Transm Infect       Date:  2002-12       Impact factor: 3.519

2.  Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.

Authors:  N J Bodsworth; R J Crooks; S Borelli; G Vejlsgaard; J Paavonen; A M Worm; N Uexkull; J Esmann; A Strand; A J Ingamells; A Gibb
Journal:  Genitourin Med       Date:  1997-04

Review 3.  Genital herpes. A guide to pharmacological therapy.

Authors:  A de Ruiter; R N Thin
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 4.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.